Epigenetic Therapy for Epithelioid Sarcoma

Scott B. Rothbart; Stephen B. Baylin

doi:10.1016/j.cell.2020.03.042

Epigenetic Therapy for Epithelioid Sarcoma

Scott B. Rothbart, Stephen B. Baylin

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Abstract

Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.

Original language	English (US)
Pages (from-to)	211
Number of pages	1
Journal	Cell
Volume	181
Issue number	2
DOIs	https://doi.org/10.1016/j.cell.2020.03.042
State	Published - Apr 16 2020

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/j.cell.2020.03.042

Cite this

@article{e7d31c84ff524172a5cd87a95b315e6c,

title = "Epigenetic Therapy for Epithelioid Sarcoma",

abstract = "Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.",

author = "Rothbart, {Scott B.} and Baylin, {Stephen B.}",

note = "Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = apr,

day = "16",

doi = "10.1016/j.cell.2020.03.042",

language = "English (US)",

volume = "181",

pages = "211",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Epigenetic Therapy for Epithelioid Sarcoma

AU - Rothbart, Scott B.

AU - Baylin, Stephen B.

PY - 2020/4/16

Y1 - 2020/4/16

N2 - Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.

AB - Tazemetostat is the first epigenetic therapy to gain FDA approval in a solid tumor. This lysine methyltransferase inhibitor targets EZH2, the enzymatic subunit of the PRC2 transcriptional silencing complex. Tumors with mutations in subunits of the SWI/SNF chromatin remodeling complex, inclusive of most epithelioid sarcomas, are sensitive to EZH2 inhibition.

UR - http://www.scopus.com/inward/record.url?scp=85083067585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083067585&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2020.03.042

DO - 10.1016/j.cell.2020.03.042

M3 - Comment/debate

C2 - 32302562

AN - SCOPUS:85083067585

SN - 0092-8674

VL - 181

SP - 211

JO - Cell

JF - Cell

IS - 2

ER -

Epigenetic Therapy for Epithelioid Sarcoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this